Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hazal Köse"'
Autor:
Uta M. Demel, Matthias Wirth, Schayan Yousefian, Le Zhang, Konstandina Isaakidis, Judith Dönig, Marlitt Böger, Nikita Singh, Hazal Köse, Simon Haas, Stefan Müller, Markus Schick, Ulrich Keller
Publikováno v:
Haematologica, Vol 108, Iss 2 (2022)
Aberrant activity of the SUMOylation pathway has been associated with MYC overexpression and poor prognosis in aggressive B-cell lymphoma (BCL) and other malignancies. Recently developed small-molecule inhibitors of SUMOylation (SUMOi) target the het
Externí odkaz:
https://doaj.org/article/0ecbee0d5cf3435ba327c7bfefdcf242
Autor:
Uta M. Demel, Marlitt Böger, Schayan Yousefian, Corinna Grunert, Le Zhang, Paul W. Hotz, Adrian Gottschlich, Hazal Köse, Konstandina Isaakidis, Dominik Vonficht, Florian Grünschläger, Elena Rohleder, Kristina Wagner, Judith Dönig, Veronika Igl, Bernadette Brzezicha, Francis Baumgartner, Stefan Habringer, Jens Löber, Björn Chapuy, Carl Weidinger, Sebastian Kobold, Simon Haas, Antonia B. Busse, Stefan Müller, Matthias Wirth, Markus Schick, Ulrich Keller
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 9 (2022)
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor
Externí odkaz:
https://doaj.org/article/07797f9821104132ba3cea7f4918f2e9
Autor:
Matthias Wirth, Hazal Köse
Publikováno v:
TheScienceBreaker. 9
One of the major challenges in cancer therapy is the recurrent emergence of resistance. In pancreatic cancer, we uncovered one such resistance mechanism. Inhibiting a protein which is highly expressed in a therapy-resistant subtype of pancreatic canc
Autor:
Josefina Doffo, Stefanos A. Bamopoulos, Hazal Köse, Felix Orben, Chuanbing Zang, Miriam Pons, Alexander T. den Dekker, Rutger W. W. Brouwer, Apoorva Baluapuri, Stefan Habringer, Maximillian Reichert, Anuradha Illendula, Oliver H. Krämer, Markus Schick, Elmar Wolf, Wilfred F. J. van IJcken, Irene Esposito, Ulrich Keller, Günter Schneider, Matthias Wirth
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 119(9):e2105691119. National Academy of Sciences
Evasion from drug-induced apoptosis is a crucial mechanism of cancer treatment resistance. The proapoptotic protein NOXA marks an aggressive pancreatic ductal adenocarcinoma (PDAC) subtype. To identify drugs that unleash the death-inducing potential
Autor:
Chuanbing Zang, Stefanos A. Bamopoulos, Alexander T. den Dekker, Oliver H. Krämer, Matthias Wirth, Markus Schick, Felix Orben, Miriam Pons, Maximillian Reichert, Ulrich Keller, Irene Esposito, Rutger W W Brouwer, Elmar Wolf, Stefan Habringer, Apoorva Baluapuri, Anuradha lllendula, Wilfred F. J. van IJcken, Günter Schneider, Josefina Doffo, Hazal Köse
Evasion from drug-induced apoptosis is a crucial mechanism of cancer treatment resistance. The pro-apoptotic protein NOXA marks an aggressive pancreatic ductal adenocarcinoma (PDAC) subtype. To identify drugs that unleash the death-inducing potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053a7c7030fdad7119b028535f6b89d4
https://doi.org/10.1101/2021.10.21.465266
https://doi.org/10.1101/2021.10.21.465266
Autor:
Uta M. Demel, Marlitt Böger, Schayan Yousefian, Corinna Grunert, Le Zhang, Paul W. Hotz, Adrian Gottschlich, Hazal Köse, Konstandina Isaakidis, Dominik Vonficht, Florian Grünschläger, Elena Rohleder, Kristina Wagner, Judith Dönig, Veronika Igl, Bernadette Brzezicha, Francis Baumgartner, Stefan Habringer, Jens Löber, Björn Chapuy, Carl Weidinger, Sebastian Kobold, Simon Haas, Antonia B. Busse, Stefan Müller, Matthias Wirth, Markus Schick, Ulrich Keller
Publikováno v:
J. Clin. Invest. 132:e152383 (2022)
The Journal of Clinical Investigations
The Journal of Clinical Investigations
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor